Search This Blog

Sunday, October 30, 2016

Bristol-Myers Squibb’s Yervoy (ipilimumab) Awarded Prix Galien USA Discovery of the Decade | BMS Newsroom

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it received the Prix Galien USA Discovery of the Decade biotech award for Yervoy (ipilimumab), the Company’s recombinant, human monoclonal antibody. In honor of the 10th anniversary of the Prix Galien awards and recognizing this decade as one of history's most productive for research, this special honor distinguishes Bristol-Myers Squibb for its innovative discovery and development of Yervoy, which is now approved in more than 50 countries for treatment of unresectable or metastatic melanoma. The award is also a testament to Bristol-Myers Squibb’s efforts to establish Immuno-Oncology as a transformational approach to treating a wide range of malignancies.



Bristol-Myers Squibb’s Yervoy (ipilimumab) Awarded Prix Galien USA Discovery of the Decade | BMS Newsroom

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.